Eczema Global Market Report 2025

The eczema market size has grown strongly in recent years. It will grow from $16.41 billion in 2024 to $17.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune diseases, the rising cases of eczema, greater regulatory approvals, the growing incidence of air pollution, and the increasing burden of allergic reactions.

The eczema market size is expected to see strong growth in the next few years. It will grow to $24.35 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be attributed to the rising demand for atopic dermatitis treatment, increasing operational activities, greater awareness of eczema, the growing use of biologics, and the expanding adoption of telemedicine platforms. Key trends in the forecast period include strategic collaborations, the development of emerging therapies, the rise of injectable drugs, and the advancement of personalized medicine.

The rising prevalence of autoimmune disorders is expected to drive the expansion of the eczema market in the coming years. Autoimmune disorders occur when the body's immune system mistakenly attacks healthy cells, tissues, or organs, leading to inflammation and damage. The growing incidence of these conditions is linked to genetic susceptibility, environmental factors, infections, dietary changes, and lifestyle influences such as stress and exposure to pollutants. Autoimmune diseases such as psoriasis, lupus, and rheumatoid arthritis are associated with dysregulated immune responses, increasing the likelihood of eczema and other inflammatory skin conditions. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Consequently, the increasing prevalence of autoimmune disorders is fueling the growth of the eczema market.

Leading companies in the eczema market are focusing on developing innovative products, such as advanced eczema care creams, to improve treatment effectiveness and meet the growing demand for specialized skincare solutions. Eczema care creams are formulated to soothe, hydrate, and protect affected skin, reducing itching, inflammation, and dryness. For instance, in September 2024, Dove, a UK-based personal care brand, launched a new Eczema Care range for babies, including the Baby Dove Eczema Care Soothing Bath Treatment and the Baby Dove Eczema Care Cream. This product line is designed specifically for infants with eczema, featuring 100% skin-natural nutrients to ensure gentleness on sensitive skin. Additionally, the formulations contain colloidal oatmeal (1%), a key ingredient known for soothing irritation and maintaining skin moisture.

In May 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for approximately $850 million. This acquisition aims to strengthen Johnson & Johnson’s position in treating atopic dermatitis (AD) and asthma by integrating innovative bispecific antibody therapies into its product portfolio. Proteologix Inc. is a US-based biotechnology company specializing in the development of bispecific antibodies for immune-mediated diseases.

Major players in the eczema market are Pfizer Inc., AbbieVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Amgen, Hoffmann-La Roche AG, Eli Lilly and Co., Siemens Healthineers AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc, Bausch Health Companies Inc., Galderma, Cadila Pharmaceuticals Ltd., LEO Pharma A/S, Almirall, Kyowa Kirin, Alliance Pharma Plc, Encore Dermatology Inc., Arcutis Inc.

North America was the largest region in the eczema market in 2024. The regions covered in eczema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the eczema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Eczema is a chronic inflammatory skin condition marked by redness, itching, dryness, and irritation. It results from a combination of genetic and environmental factors, leading to a weakened skin barrier and an overactive immune response. While eczema can affect individuals of all ages, it is more common in children. The condition often occurs in flare-ups triggered by allergens, irritants, stress, or climate changes.

The primary types of eczema include atopic dermatitis, contact dermatitis, seborrheic dermatitis, and other variations. Atopic dermatitis, commonly referred to as eczema, is a chronic skin disorder characterized by itchy, red, and inflamed skin, often aggravated by allergens, irritants, or stress. Treatment options for eczema include topical treatments, oral medications, biologics, and phototherapy. The condition affects various age groups, including children, adults, and the elderly, and is managed across different healthcare settings such as hospitals, clinics, dermatology centers, home care, and pharmacies.

The eczema market research report is one of a series of new reports that provides eczema market statistics, including the eczema industry global market size, regional shares, competitors with the eczema market share, detailed eczema market segments, market trends, and opportunities, and any further data you may need to thrive in the eczema industry. This eczema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The eczema market consists of revenues earned by entities by providing services such as diagnosis and consultation services, prescription and medication services, phototherapy services, allergy testing and immunotherapy, and skin barrier repair therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The eczema market also includes sales of antihistamines, topical corticosteroids, calcineurin inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.